3/28
08:41 am
iva
Inventiva S.A. (NASDAQ: IVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.
Low
Report
Inventiva S.A. (NASDAQ: IVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.
3/26
04:00 pm
iva
Inventiva reports its 2024 full year results and provides a business update
Medium
Report
Inventiva reports its 2024 full year results and provides a business update
3/19
04:00 pm
iva
Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results
Low
Report
Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results
2/26
04:00 pm
iva
Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment
Medium
Report
Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment
2/21
08:16 am
iva
Inventiva S.A. (NASDAQ: IVA) is now covered by analysts at TD Cowen. They set a "buy" rating and a $10.00 price target on the stock.
Medium
Report
Inventiva S.A. (NASDAQ: IVA) is now covered by analysts at TD Cowen. They set a "buy" rating and a $10.00 price target on the stock.
2/20
04:00 pm
iva
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
Low
Report
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
2/10
04:00 pm
iva
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
Medium
Report
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
1/30
12:45 pm
iva
Inventiva S.A. (NASDAQ: IVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.
Medium
Report
Inventiva S.A. (NASDAQ: IVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.
1/29
04:00 pm
iva
Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology
Medium
Report
Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology
1/24
04:00 pm
iva
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Low
Report
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
1/22
04:00 pm
iva
Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025
High
Report
Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025